Yunnan Baiyao released the third quarter report, with increased R & D investment and emphasis on strengthening the layout of biological drugs

On October 27, Yunnan Baiyao released the third quarter report of 2019 According to the report, the total operating revenue of Yunnan Baiyao in the third quarter was 7.748 billion yuan, with a year-on-year growth rate of 13.42%, R & D cost of 42.1196 million yuan, with a year-on-year growth of 25.519 million yuan, with a year-on-year growth of 68%; sales cost of 824 million yuan, with a year-on-year growth of 656 million yuan, with a year-on-year growth of 25.6%, compared with the total operating revenue of 216.46% in the first three quarters Billion yuan, up 8.36% year-on-year from 19.976 billion yuan in the same period of last year; 107 million yuan for R & D, up 37.11% year-on-year from 78.18 million yuan last year; 2.763 billion yuan for sales in the first three quarters, up 7.4% year-on-year Compared with the data of previous years, it is not difficult to find that the growth rate of Yunnan Baiyao's business revenue in 2019 has declined, and the proportion of sales growth has basically maintained, but the proportion of R & D investment growth has increased relatively It can be predicted that the proportion of R & D in Yunnan Baiyao's strategic planning has increased It is believed that in the future, no matter the enterprise's own R & D or other investment methods All of our actions will be greatly improved On October 25, Yunnan Baiyao published the announcement on the use of its own funds for foreign investment, which invested 350 million yuan as a cornerstone investor to participate in the subscription of the initial public offering shares of China antibody Pharmaceutical Co., Ltd on the Hong Kong stock exchange, and successfully distributed bio pharmaceuticals It also confirms the above view It is understood that China antibody pharmaceutical was founded in April 2001, and is mainly engaged in the development of targeted specific antibody drugs for the treatment of malignant tumors and consumptive diseases In the world, Chinese antibody pioneered the "framework reengineering" antibody engineering technology platform, which can develop and reserve competitive antibody products In the early stage, we have developed the global innovative monoclonal antibody products, obtained the clinical research approval for the treatment of non Hodgkin's lymphoma, systemic lupus erythematosus and rheumatoid arthritis in China, and the research on lymphoma has entered the phase II clinical trial stage, and its anti body production capacity also has outstanding advantages At present, there are 6 drugs under research in the pipeline of antibody pharmaceutical products in China, focusing on the field of immune diseases Yunnan Baiyao also clearly stated in the above announcement that the investment is conducive to improving the efficiency of the company's capital utilization, promoting the company's strategic layout with the help of capital market advantages, strengthening the company's layout in the field of biomedicine, and improving the company's comprehensive competitiveness Editor in charge: penicillin statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.